The DOI matches its Crossref record.
The pharmacokinetics of azithromycin in human serum and tissues
Abstract
The pharmacokinetics of azithromycin, a new azalide antibiotic, were examined in man. Approximately 37% of a single oral dose of 500 mg was bioavailable and produced a peak serum concentration of 0.4 mg/l. Multiple dose regimens (two doses of 500 mg separated by 12 h and followed by 500 mg qds for five days, or two doses of 250 mg separated by 12 h and followed by 250 mg qds for nine days) produced only slight increases in peak serum concentrations. The serum protein binding of azithromycin declined from about 50% at 0.02 mg/l to 12% at 0.5 mg/l. Tissue concentrations of azithromycin were much higher than serum concentrations. After two 250 mg doses 12 h apart, peak azithromycin concentrations exceeded 3 mg/kg in prostate, tonsil and many other tissues. Concentrations in tissues declined with apparent half-lives of 2.3 days in prostate and 3.2 days in tonsil. The high tissue concentrations suggest that proposed standard dosage regimens of 500 mg qds on day 1 followed by 250 mg qds for four days, or three daily dosages of 500 mg, will produce tissue concentrations above 3 mg/kg in a variety of tissues. Since these tissue concentrations exceed the MICs of relevant pathogens, these dosage regimens should be effective against respiratory tract and soft-tissue infections. A single 1 g dose may be effective in the treatment of many sexually transmitted diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Crump, J. A., Sjölund-Karlsson, M., Gordon, M. A., & Parry, C. M. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00002-15 · Cited by 1,156
Azithromycin and the Risk of Cardiovascular Death
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1003833 · Cited by 954
Gupta, S., Leatham, E. W., Carrington, D., Mendall, M. A., Kaski, J. C., & Camm, A. J. (1997) · Circulation · doi:10.1161/01.cir.96.2.404 · Cited by 706
Azithromycin: Mechanisms of action and their relevance for clinical applications
Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.003 · Cited by 661
Malhotra-Kumar, S., Lammens, C., Coenen, S., Van Herck, K., & Goossens, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60235-9 · Cited by 545
2012 European guideline on the diagnosis and treatment of gonorrhoea in adults
Bignell, C., Unemo, M., The European STI Guidelines Editorial Board, Radcliffe, K., Jensen, J. S., Babayan, K., Barton, S., Cusini, M., Gomberg, M., Janier, M., et al. (2013) · International Journal of STD & AIDS · doi:10.1177/0956462412472837 · Cited by 483
The macrolide antibiotic renaissance
Dinos, G. P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13936 · Cited by 471
Havlir, D. V., Dubé, M. P., Sattler, F. R., Forthal, D. N., Kemper, C. A., Dunne, M. W., Parenti, D. M., Lavelle, J. P., White, A. C., Witt, M. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608083350604 · Cited by 329
Sorsa, T., Gursoy, U. K., Nwhator, S., Hernandez, M., Tervahartiala, T., Leppilahti, J., Gursoy, M., Könönen, E., Emingil, G., Pussinen, P. J., et al. (2016) · Periodontology 2000 · doi:10.1111/prd.12101 · Cited by 312
Review of Macrolides and Ketolides: Focus on Respiratory Tract Infections
Zhanel, G. G., Dueck, M., Hoban, D. J., Vercaigne, L. M., Embil, J. M., Gin, A. S., & Karlowsky, J. A. (2001) · Drugs · doi:10.2165/00003495-200161040-00003 · Cited by 304
Peters, D. H., Friedel, H. A., & McTavish, D. (1992) · Drugs · doi:10.2165/00003495-199244050-00007 · Cited by 304
The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms
Zimmermann, P., Ziesenitz, V. C., Curtis, N., & Ritz, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00302 · Cited by 303
Zarogoulidis, P., Papanas, N., Kioumis, I., Chatzaki, E., Maltezos, E., & Zarogoulidis, K. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1161-x · Cited by 299
Azithromycin in control of trachoma
Schachter, J., West, S. K., Mabey, D., Dawson, C. R., Bobo, L., Bailey, R., Vitale, S., Quinn, T. C., Sheta, A., Sallam, S., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12387-5 · Cited by 296
Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid
Kiem, S., & Schentag, J. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00133-06 · Cited by 289
The Macrolides: Erythromycin, Clarithromycin, and Azithromycin
Alvarez-Elcoro, S., & Enzler, M. J. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.6.613 · Cited by 282
Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M.-P., Tulkens, P. M., & Van Bambeke, F. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.841-851.2006 · Cited by 266
Kuschner, R. A., Trofa, A. F., Thomas, R. J., Hoge, C. W., Pitarangsi, C., Amato, S., Olafson, R. P., Echeverria, P., Sadoff, J. C., & Taylor, D. N. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.3.536 · Cited by 242
Azithromycin-resistant syphilis infection: San Francisco, California, 2000–2004.
Mitchell, S. J., Engelman, J., Kent, C. K., Lukehart, S. A., Godornes, C., & Klausner, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/498899 · Cited by 137
Yadav, P., Warkar, S. G., & Kumar, A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146662 · Cited by 13
Metadata
- Authors
- Foulds, G., Shepard, R. M., & Johnson, R. B.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1990-01-01
- Volume
- 25
- Issue
- suppl A
- Pages
- 73-82
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2006148788
- Cited by
- 755
- References
- 0
- FWCI
- 36.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.